List of Excipients in Branded Drug RISPERDAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	RISPERDAL	risperidone	21695-113	ANHYDROUS LACTOSE
Rebel Distributors Corp	RISPERDAL	risperidone	21695-113	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	RISPERDAL	risperidone	21695-113	HYPROMELLOSES
Rebel Distributors Corp	RISPERDAL	risperidone	21695-113	MAGNESIUM STEARATE
Rebel Distributors Corp	RISPERDAL	risperidone	21695-113	PROPYLENE GLYCOL

RISPERDAL Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

RISPERDAL, the brand name for risperidone, is a mature antipsychotic franchise with several dosage forms: immediate-release tablets, orally disintegrating tablets, oral solution, and long-acting injectable microspheres. Its original compound and core oral formulation barriers have expired, making commercial value depend on differentiated delivery, pediatric usability, manufacturing reliability, and regulatory positioning rather than basic risperidone composition claims.

The strongest excipient opportunities are in taste masking, orally disintegrating technology, low-volume pediatric liquids, moisture-controlled solid dosage forms, and long-acting injectable microsphere manufacturing. The highest technical barrier is the Risperdal Consta-type PLGA microsphere system.

What dosage forms and excipients does RISPERDAL use?

RISPERDAL uses different excipient strategies across its immediate-release, orally disintegrating, liquid, and injectable products.

Product	Dosage form	Key excipient strategy	Commercial relevance
RISPERDAL tablets	Immediate-release film-coated tablet	Lactose-based diluent system, microcrystalline cellulose, starch, magnesium stearate, coating agents and colorants	Low technical barrier; generic competition is extensive
RISPERDAL M-TAB	Orally disintegrating tablet	Mannitol, glycine, citric acid or citrate salts, crospovidone, poloxamer and sweetening or flavor-supporting components	Pediatric and swallowing-difficulty differentiation
RISPERDAL oral solution	1 mg/mL oral liquid	Purified water, tartaric acid, benzoic acid and pH adjustment components	Pediatric dosing flexibility and adherence
RISPERDAL Consta	Intramuscular extended-release microspheres	Risperidone encapsulated in PLGA microspheres, reconstituted with a proprietary diluent system	Highest manufacturing and formulation barrier

The precise excipient composition varies by market, strength, manufacturer and manufacturing site. The U.S. prescribing information identifies the inactive ingredients for each branded product and should control any formulation comparison.[1]

How does the RISPERDAL tablet excipient system work?

The conventional tablet uses standard direct-compression or granulation excipients. Lactose and microcrystalline cellulose provide bulk and compressibility. Starch supports disintegration. Magnesium stearate reduces tooling friction but can affect dissolution if over-lubrication occurs.

The film coat provides visual identification, swallowability and protection from handling. It is unlikely to provide a meaningful current exclusivity barrier because these materials are widely used and generic products have entered the market.

For generic manufacturers, the principal development issues are:

• Matching dissolution across strengths.
• Controlling tablet hardness and friability.
• Managing lactose-related compression behavior.
• Avoiding excess magnesium stearate that slows dissolution.
• Reproducing color, coat weight and appearance where comparative product expectations matter.
• Demonstrating pharmaceutical equivalence and bioequivalence under the applicable abbreviated new drug application pathway.

What excipients are used in RISPERDAL M-TAB?

RISPERDAL M-TAB uses an orally disintegrating platform based on rapidly wettable, highly porous excipient architecture. Mannitol contributes bulk, mouthfeel and cooling sensation. Glycine can improve palatability and tablet structure. Crospovidone promotes rapid disintegration. Citrate and acid components support taste and microenvironment control. Poloxamer may improve wetting and powder processing.

The opportunity is not simply faster disintegration. A commercially competitive orally disintegrating risperidone product must control:

• Mechanical strength during packaging and transport.
• Disintegration time without excessive friability.
• Bitter active pharmaceutical ingredient taste.
• Moisture sensitivity.
• Unit-dose packaging cost.
• Dose uniformity at low tablet strengths.

The product’s excipient architecture can be replicated in broad terms, but a manufacturer may obtain commercial differentiation through a distinct orally disintegrating platform, taste-masking system, or packaging configuration. Such differentiation generally requires a new regulatory strategy and may not support broad patent protection by itself.

What excipients are used in RISPERDAL oral solution?

RISPERDAL oral solution is an aqueous 1 mg/mL product. The formulation uses acidification and preservation rather than a complex suspension system. The labeled formulation includes purified water, tartaric acid, benzoic acid and sodium hydroxide for pH adjustment.[1]

This design has several advantages:

• It avoids sedimentation and redispersion problems associated with suspensions.
• It permits flexible pediatric dose measurement.
• It supports administration through an oral dosing device.
• It reduces dependence on complex solubilizers.

The principal technical risks are chemical stability, preservative performance, container compatibility and taste. Risperidone is bitter, so the absence of a sophisticated flavor system creates a development opportunity for differentiated products.

What pediatric excipient opportunities exist for risperidone liquids?

Risperidone has FDA-labeled pediatric uses, including irritability associated with autistic disorder in children and adolescents and bipolar mania or mixed episodes in certain pediatric populations.[1] These indications create a clear need for age-appropriate administration.

Commercially relevant liquid strategies include:

• Improved taste masking without excessive sugar.
• Alcohol-free and propylene-glycol-minimized systems.
• Unit-dose sachets or premeasured oral syringes.
• Higher concentration products that reduce administration volume.
• Preservative systems suitable for repeated opening.
• Tamper-evident packaging.
• Excipient systems suitable for children with sensory or swallowing limitations.

Any modified concentration would need a full concentration, dosing-device and safety assessment. A more concentrated product can reduce liquid burden but can also increase dosing error risk.

Which RISPERDAL formulation has the strongest commercial opportunity?

The long-acting injectable microsphere formulation has the strongest technical opportunity, while pediatric oral products have the clearest near-term usability opportunity.

Opportunity	Technical barrier	Regulatory burden	Likely commercial position
Standard tablets	Low	ANDA	Price-driven generic market
Oral solution	Moderate	ANDA or differentiated NDA/505(b)(2), depending on changes	Pediatric and adherence niche
Orally disintegrating tablet	Moderate	ANDA or differentiated pathway	Swallowing and administration niche
Taste-masked pediatric liquid	Moderate to high	New product-specific review	Potentially differentiated
Long-acting PLGA microspheres	High	Complex generic or NDA/505(b)(2) pathway	Highest barrier and value
Alternative long-acting delivery system	High	New drug or hybrid regulatory pathway	Potentially substantial but capital intensive

What protects RISPERDAL and when did exclusivity expire?

Risperidone’s original U.S. compound and oral-product exclusivity periods have expired. FDA-approved generic risperidone tablets, orally disintegrating tablets and oral solutions have been available for years. The product therefore has no meaningful current U.S. exclusivity advantage in conventional oral dosage forms.[2]

Key milestones include:

Milestone	Approximate timing
Original FDA approval of RISPERDAL	1990s
Oral solution and orally disintegrating product expansion	1990s
RISPERDAL Consta approval	2003
Generic oral risperidone entry	2000s
Core oral-product patent protection	Expired
Consta-related exclusivity and patent barriers	Largely expired or no longer sufficient to prevent broad market entry

Patent expiration dates depend on the specific patent, jurisdiction, terminal disclaimers, pediatric extensions and listed product. The FDA Orange Book remains the controlling source for U.S. listed patents and regulatory exclusivity.[2]

What is the Orange Book status of RISPERDAL?

The Orange Book historically listed RISPERDAL products and related patents, but the commercial significance of those listings has declined as generic oral products entered the market. The relevant distinction is between:

• Compound and conventional oral formulation patents, which are no longer meaningful barriers.
• Method-of-use patents, which may have had narrower scope and limited commercial effect.
• Long-acting injectable formulation and manufacturing patents, which presented a more substantial barrier.
• Device, packaging and process claims, which can create narrower litigation or licensing exposure without controlling the entire market.

An Orange Book listing does not by itself establish that a patent will withstand validity or infringement challenges. Generic applicants may file Paragraph IV certifications against listed patents, while other patents may be addressed through Paragraph III certifications or non-infringement positions under the Hatch-Waxman framework.[3]

What Paragraph IV challenges and generic entry risks affect RISPERDAL?

For oral RISPERDAL, Paragraph IV risk is largely historical because generic entry has already occurred. The relevant commercial risk is price erosion rather than initial market disruption.

For long-acting risperidone, generic entry is more complex. A competitor must address:

• Microsphere particle-size distribution.
• Drug loading and encapsulation efficiency.
• In-vitro release profile.
• Residual solvent levels.
• Reconstitution behavior.
• Syringeability and needle compatibility.
• Injection-site tolerability.
• Stability of the reconstituted product.
• Clinical or comparative requirements imposed by FDA.

A microsphere product can be pharmaceutically equivalent in active ingredient yet difficult to reproduce in release behavior. This is where manufacturing know-how and process control can remain commercially relevant after core patents expire.

Which companies are challenging RISPERDAL?

Multiple generic manufacturers have marketed oral risperidone products in the United States and other jurisdictions. The oral market includes large generic suppliers and regional manufacturers. The competitive field for long-acting injectable risperidone is narrower because manufacturing and regulatory requirements are materially higher.

A complete current list of ANDA holders, active Paragraph IV notices and pending litigation requires a live FDA and court-docket review. Product-level competitive risk should therefore be assessed separately for each dosage form rather than treating "generic risperidone" as one market.

What patent strategy remains available for risperidone products?

New patent value is more likely to arise from formulation and manufacturing claims than from the risperidone molecule itself.

Formulation patents

Potential claim areas include:

• Specific PLGA compositions and polymer ratios.
• Microsphere particle-size distributions.
• Encapsulation processes.
• Controlled-release profiles.
• Stabilized aqueous reconstitution systems.
• Taste-masked oral liquids.
• Low-moisture orally disintegrating tablets.
• Specific preservative and buffer combinations.
• Device-integrated dosing systems.
• Combination products with adherence monitoring.

A formulation patent is stronger when it links a defined composition to measurable performance, such as release duration, stability, bioavailability or reduced injection-site reactions. Broad claims to routine excipients such as mannitol, lactose or magnesium stearate are unlikely to create durable protection without a novel functional relationship.

Method-of-use patents

Risperidone method-of-use opportunities may include:

• Pediatric administration regimens.
• Conversion protocols from oral to long-acting therapy.
• Patient populations defined by adherence or relapse risk.
• Dosing intervals or loading regimens.
• Treatment methods linked to pharmacokinetic exposure.

Method-of-use claims can be commercially useful when they align with labeled prescribing behavior. Their enforcement value is weaker when the same product is prescribed for multiple indications and generic substitution is difficult to detect.

Manufacturing and process patents

Manufacturing claims may have the greatest practical value for long-acting injectable risperidone. Relevant subject matter includes:

• Emulsion formation.
• Solvent extraction.
• Polymer degradation control.
• Microsphere drying.
• Drug distribution within particles.
• Batch-to-batch release consistency.
• Sterility assurance.
• Reconstitution and filling.

Process patents can create a barrier even when competitors can legally sell the same active ingredient. They are most valuable when the process is difficult to design around and produces a clinically relevant product profile.

How does RISPERDAL compare with competing risperidone products?

RISPERDAL competes with generic oral risperidone and other long-acting antipsychotics.

Product category	Main advantage	Main weakness	Excipient opportunity
Generic risperidone tablet	Low cost and broad availability	Limited differentiation	Compression, coating and stability
Generic oral solution	Flexible dosing	Taste and measurement burden	Taste masking and dosing devices
Generic ODT risperidone	Easier administration	Moisture and friability concerns	Fast disintegration and palatability
RISPERDAL Consta-type microsphere	Long-acting adherence support	Injection and reconstitution complexity	PLGA process and release control
Paliperidone palmitate products	Longer dosing intervals in some products	Higher acquisition cost	Suspension stability and injection delivery
Aripiprazole long-acting products	Distinct pharmacology and dosing options	Different tolerability and formulation profile	Suspension and depot delivery systems

Paliperidone is the major related-product comparator because it is the principal active metabolite of risperidone and is available in long-acting formulations. Aripiprazole long-acting products compete for adherence-focused treatment but do not share the same active ingredient or excipient platform.

What is the FDA regulatory status of RISPERDAL products?

RISPERDAL products are FDA-approved prescription medicines. The product line includes oral and long-acting injectable dosage forms with different labeling, administration requirements and inactive ingredients.[1]

The regulatory pathway depends on the proposed product:

• A conventional generic tablet may qualify for an ANDA.
• A generic oral solution may require comparative pharmaceutical and bioequivalence work.
• An ODT may require additional control of disintegration, packaging and in-vitro performance.
• A complex microsphere injectable may require a more demanding ANDA program or another FDA pathway depending on product comparability.
• A materially different concentration, delivery device, indication or formulation may require an NDA or 505(b)(2) application.

FDA’s guidance for complex generic products is relevant to long-acting injectable development because active-ingredient sameness alone does not establish equivalence for a complex delivery system.[4]

What licensing and partnership opportunities exist?

Licensing opportunities are strongest where a company has a platform rather than a simple risperidone copy.

Potential deal structures include:

1. Regional licensing of generic oral products in markets where branded prescribing remains strong.
2. Technology licensing for taste masking or pediatric liquid delivery.
3. Contract development and manufacturing of PLGA microspheres.
4. Co-development of a long-acting risperidone product.
5. Licensing of injection devices, prefilled systems or reconstitution technologies.
6. Partnerships linking risperidone delivery with adherence monitoring.

A conventional tablet license is likely to be price sensitive and volume driven. A microsphere or pediatric-delivery license can support higher value if it reduces development time, improves regulatory comparability or solves a measurable administration problem.

What revenue exposure does RISPERDAL create?

Revenue exposure is concentrated in formulation and channel differences rather than molecule-level exclusivity.

Revenue segment	Exposure profile
Branded oral tablets	High generic erosion
Branded oral solution	Moderate erosion, with pediatric and formulation niches
Branded ODT	Moderate erosion, depending on market and substitution rules
Long-acting injectable	Greater resilience where generic competition is limited
Hospital and institutional purchasing	Price pressure but potentially stable volume
Pediatric and adherence-focused channels	Higher value for administration convenience

Janssen has not consistently reported standalone global RISPERDAL revenue in public financial reporting. Product-level revenue estimates therefore require external prescription and sales datasets. The commercial assessment should separate branded sales, authorized generics, independent generics and long-acting injectable sales.

How strong is the RISPERDAL patent estate?

The estate is weak for conventional oral risperidone and stronger for complex injectable delivery.

• Compound protection: expired.
• Standard tablet protection: expired or commercially ineffective.
• Oral solution protection: limited current barrier.
• ODT protection: largely vulnerable to generic competition.
• Long-acting microsphere protection: historically stronger, with manufacturing and equivalence barriers remaining relevant.
• Trade secrets: potentially important for microsphere process parameters and scale-up.
• Regulatory exclusivity: no current broad exclusivity should be assumed for mature oral products.

The most defensible commercial position is a product-specific combination of formulation patents, process know-how, regulatory data and manufacturing capacity. Excipients alone rarely sustain a strong estate unless they produce a demonstrated technical effect.

Key Takeaways

• RISPERDAL’s oral formulation franchise is mature and exposed to generic price competition.
• The best oral opportunities are pediatric taste masking, improved dosing devices and robust ODT systems.
• The strongest technical barrier is the PLGA microsphere platform used for long-acting risperidone.
• Formulation and manufacturing patents are more valuable than broad excipient claims.
• Generic oral entry risk is established; long-acting injectable entry risk is more dependent on complex-product equivalence.
• FDA regulatory strategy must be selected by dosage form, not by active ingredient alone.
• Commercial opportunities are strongest in differentiated delivery, contract manufacturing and regional licensing.
• Product-level revenue exposure is not publicly disclosed consistently and should not be inferred from total antipsychotic franchise sales.

FAQs About RISPERDAL Excipients and Commercial Strategy

Can a company sell a new risperidone oral solution using different excipients?

Yes. A different excipient system may support an alternative formulation, but the product must satisfy FDA requirements for pharmaceutical quality, stability, bioequivalence or clinical performance, preservative effectiveness and dosing accuracy.

Is a risperidone orally disintegrating tablet still commercially attractive?

It can be attractive in pediatric, geriatric and swallowing-difficulty populations. The commercial case depends on taste, packaging, tablet robustness and payer substitution, not merely on rapid disintegration.

Are PLGA microspheres the main barrier to generic Risperdal Consta?

They are a major barrier. Competitors must reproduce release behavior, particle characteristics, drug loading, sterility, reconstitution and injection performance, not just the risperidone dose.

Can excipient suppliers obtain patents around RISPERDAL formulations?

Potentially, but routine use of common excipients is unlikely to provide strong protection. The better patent position comes from a defined excipient combination with a measurable technical result, such as improved stability, taste masking or controlled release.

Does RISPERDAL have biosimilar risk?

No. Risperidone is a chemically synthesized small molecule, so the relevant competitors are generic drugs and complex generics, not biosimilars.

References

1. U.S. Food and Drug Administration. (2024). RISPERDAL (risperidone) prescribing information. Janssen Pharmaceuticals, Inc.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development: Risperidone and complex injectable products. FDA.